Corindus Vascular Robotics (OTC:CVRS) said today it is working with the Mayo Clinic to launch preclinical studies exploring the use of telestenting, a robotic treatment for percutaneous coronary interventions which can be operated by physicians in remote locations.
The Waltham, Mass.-based surgical robotics company said that there is a global shortage of PCI-capable operators, and that telestenting could serve as a solution to geographic and workforce barriers that prohibit the use of PCI therapy in rural and underserved populations globally.